XML 64 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)
$ / shares in Units, € in Millions, $ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2023
EUR (€)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Apr. 27, 2023
USD ($)
$ / shares
Mar. 13, 2023
USD ($)
$ / shares
Disclosure of detailed information about business combination [line items]            
Net cash flow on acquisition | € [1] € 2,465   € 977 € 992    
Provention Bio            
Disclosure of detailed information about business combination [line items]            
Investments, ownership percentage           3.00%
Future royalties receivable, value           $ 210
Provention Bio            
Disclosure of detailed information about business combination [line items]            
Purchase price per share (in USD per share) | $ / shares         $ 25.00 $ 25.00
Cash transferred           $ 2,800
Equity interest in acquiree held before acquisition date         $ 68  
Consideration transferred, acquisition-date fair value         2,806  
Identifiable intangible assets recognised as of acquisition date         $ 2,839  
Net cash flow on acquisition   $ 2,722        
[1] For the six months ended June 30, 2023, this line item includes the net cash outflow arising from the acquisition of Provention Bio Inc. (see Note B.1.1.). For the six months ended June 30, 2022 and the year ended December 31, 2022, it includes the net cash outflow arising from the acquisition of Amunix.